Allarity Therapeutics Stock Performance
| ALLR Stock | USD 1.02 0.03 3.03% |
On a scale of 0 to 100, Allarity Therapeutics holds a performance score of 3. The firm shows a Beta (market volatility) of 0.57, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Allarity Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Allarity Therapeutics is expected to be smaller as well. Please check Allarity Therapeutics' accumulation distribution, market facilitation index, as well as the relationship between the downside variance and sortino ratio , to make a quick decision on whether Allarity Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Allarity Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak essential indicators, Allarity Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:30 | Last Split Date 2024-09-11 |
1 | Allarity Therapeutics, Inc. Short Interest Update | 01/17/2025 |
2 | Acquisition by Benjamin Laura of 25000 shares of Allarity Therapeutics at 1.01 subject to Rule 16b-3 | 01/22/2025 |
3 | Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle ... | 01/30/2025 |
4 | Allarity Therapeutics and Xilio Therapeutics Financial Contrast | 02/05/2025 |
5 | Acquisition by Alexander Epshinsky of 29496 shares of Allarity Therapeutics subject to Rule 16b-3 | 02/14/2025 |
6 | Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit | 02/26/2025 |
7 | Allarity Therapeutics Announces Board Authorization of 5 Million Share Repurchase Program | 03/03/2025 |
8 | Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission | 03/13/2025 |
9 | ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm | 03/19/2025 |
| Begin Period Cash Flow | 2 M |
Allarity |
Allarity Therapeutics Relative Risk vs. Return Landscape
If you would invest 101.00 in Allarity Therapeutics on December 24, 2024 and sell it today you would earn a total of 1.00 from holding Allarity Therapeutics or generate 0.99% return on investment over 90 days. Allarity Therapeutics is currently generating 0.2958% in daily expected returns and assumes 7.722% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than Allarity, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Allarity Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Allarity Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Allarity Therapeutics, and traders can use it to determine the average amount a Allarity Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0383
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ALLR | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.72 actual daily | 68 68% of assets are less volatile |
Expected Return
| 0.3 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Allarity Therapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Allarity Therapeutics by adding it to a well-diversified portfolio.
Allarity Therapeutics Fundamentals Growth
Allarity Stock prices reflect investors' perceptions of the future prospects and financial health of Allarity Therapeutics, and Allarity Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Allarity Stock performance.
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | (12.74 M) | ||||
| Shares Outstanding | 1.41 M | ||||
| Price To Book | 0.34 X | ||||
| Gross Profit | (36.35 M) | ||||
| EBITDA | (12.08 M) | ||||
| Net Income | (11.9 M) | ||||
| Cash And Equivalents | 7.73 M | ||||
| Cash Per Share | 0.75 X | ||||
| Total Debt | 1.3 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 0.88 X | ||||
| Book Value Per Share | 16.98 X | ||||
| Cash Flow From Operations | (12.74 M) | ||||
| Earnings Per Share | (10.98) X | ||||
| Market Capitalization | 2.06 M | ||||
| Total Asset | 11.86 M | ||||
| Retained Earnings | (94.45 M) | ||||
| Working Capital | (12.2 M) | ||||
About Allarity Therapeutics Performance
Assessing Allarity Therapeutics' fundamental ratios provides investors with valuable insights into Allarity Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Allarity Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -5.3 K | -5.1 K | |
| Return On Tangible Assets | (5.38) | (5.65) | |
| Return On Capital Employed | 7.00 | 7.35 | |
| Return On Assets | (1.15) | (1.21) | |
| Return On Equity | 3.89 | 4.09 |
Things to note about Allarity Therapeutics performance evaluation
Checking the ongoing alerts about Allarity Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Allarity Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Allarity Therapeutics had very high historical volatility over the last 90 days | |
| Allarity Therapeutics has some characteristics of a very speculative penny stock | |
| Allarity Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Allarity Therapeutics currently holds 1.3 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Allarity Therapeutics has a current ratio of 0.86, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Allarity Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (11.9 M) with loss before overhead, payroll, taxes, and interest of (36.35 M). | |
| Allarity Therapeutics currently holds about 7.73 M in cash with (12.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. | |
| Roughly 12.0% of Allarity Therapeutics shares are held by company insiders | |
| Latest headline from prnewswire.com: ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm |
- Analyzing Allarity Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Allarity Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Allarity Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Allarity Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Allarity Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Allarity Therapeutics' stock. These opinions can provide insight into Allarity Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Allarity Stock Analysis
When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.